Belarus Pharmaceuticals and Healthcare Report Q1 2015

Business Monitor International
December 17, 2014
87 Pages - SKU: BMI5416294
Countries covered: Belarus

Belarus Pharmaceuticals and Healthcare Report Q1 2015

BMI View: The Belarusian market will suffer from the impact of depreciation and economic instability asthe country's economy becomes ever more reliant on Russian loans to function. Furthermore, wage growthmandated by the government will become unsustainable, threatening to dampen internal consumption.

Belarus will present little reward for high risk for most pharmaceutical companies in the region.

Headline Expenditure Projections

Pharmaceuticals: BYR8,927bn in 2013 (USD1.00bn) to BYR11,490bn (USD1.09bn) in 2014; +28.7% inlocal currency terms and +9.2% in US dollar terms.

Healthcare: BYR29,768bn (USD3.34bn) in 2013 to BYR37,249bn (USD3.55bn) in 2014; +25.1% in localcurrency terms and +6.1% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Tanzania Pharmaceuticals and Healthcare Report Q2 2015 by Business Monitor International
Tanzania Pharmaceuticals and Healthcare Report Q2 2015BMI View: Tanzania's pharmaceutical market will continue to see growth with the continuing expansion ofthe country's National Health Insurance ...
Singapore Pharmaceuticals and Healthcare Report Q2 2015 by Business Monitor International
Singapore Pharmaceuticals and Healthcare Report Q2 2015BMI View: Singapore will remain a highly attractive manufacturing base for international pharmaceuticalcompanies due to minimal levels of operational ...
Poland Pharmaceuticals and Healthcare Report Q2 2015 by Business Monitor International
Poland Pharmaceuticals and Healthcare Report Q2 2015BMI View: The Polish pharmaceutical market is heavily dependent on public healthcare spending; anynegative economic developments will have an ...
Peru Pharmaceuticals and Healthcare Report Q2 2015 by Business Monitor International
Peru Pharmaceuticals and Healthcare Report Q2 2015BMI View: Longstanding trade agreements with the US and EU, along with efficient regulations for qualitycontrol will continue to ...
See all reports like this >>

More Belarus Prescription Drugs reports

Pharmaceuticals and Healthcare Report - Belarus Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Belarus Q4 2014BMI View: The Belarusian market will suffer from the impact of prolonged rouble depreciation andeconomic instability. ...
Belarus Pharmaceuticals and Helathcare Report Q3 2012 by Business Monitor International
BMI View: The short-term outlook for the Belarusian pharmaceutical market is deeply uncertain due toexchange-rate volatility and the economy’s lack of capacity for progress without ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!